Table 1.

Baseline patient characteristics.

	Total	Prostate cancer (+)	Prostate cancer (−)	P
No. of patients	421	100 (23.8)	321 (76.2)
Age at initial PBx (yr)	66.1 ± 8.1	67.9 ± 7.3	65.5 ± 8.29	0.009
PSA at initial PBx (ng/mL)	8.90 ± 7.13	8.46 ± 6.51	9.04 ± 7.32	0.533
PSA at repeat PBx (ng/mL)	10.01 ± 8.77	10.67 ± 10.13	9.80 ± 8.31	0.426
Prostate volume (cc)	47.62 ± 22.94	38.16 ± 16.32	50.66 ± 23.94	< 0.001
PSA density at initial PBx (ng/mL/cc)	0.20 ± 0.14	0.24 ± 0.18	0.19 ± 0.12	0.024
PSA density at repeat PBx (ng/mL/cc)	0.23 ± 0.23	0.29 ± 0.24	0.22 ± 0.17	0.016
No. of PBx core (n)	13.34 ± 4.42	14.24 ± 5.18	13.06 ± 0.41	0.039
No. of PSA down at the first follow up after initial PBx	106 (25.2)	29 (29.0)	77 (24.0)	0.849
Levels of PSA down at the first follow up after initial PBx (ng/mL)	0.15 ± 0.91	−1.58 ± 9.05	0.68 ± 9.07	0.073
PSAV before the initial PBx (ng/mL/yr)	0.56 ± 27.15	2.88 ± 15.31	−0.06 ± 29.55	0.619
PSAV before the repeat PBx (ng/mL/yr)	0.31 ± 25.68	−3.17 ± 48.52	1.41 ± 11.28	0.461
PSAV between the initial and repeat PBx (ng/mL/yr)	4.51 ± 34.94	8.93 ± 44.78	3.11 ± 31.21	0.258
Average of PSA levels before the initial PBx (ng/mL)	8.76 ± 7.38	8.65 ± 7.94	8.80 ± 7.21	0.875
Standard deviation of PSA levels before the initial PBx (ng/mL)	3.20 ± 6.53	1.85 ± 3.23	3.66 ± 7.25	0.008
Average of PSA levels for the follow-up duration (ng/mL)	9.26 ± 6.75	9.37 ± 7.41	9.22 ± 6.54	0.866
Standard deviation of PSA levels for the follow-up duration (ng/mL)	2.73 ± 4.31	2.52 ± 4.47	2.79 ± 4.26	0.656
Average of PSA levels after the repeat PBx (ng/mL)	7.29 ± 6.55		7.29 ± 6.55	0.812
Standard deviation of PSA levels after the repeat PBx (ng/mL)	2.93 ± 6.32		2.93 ± 6.32	0.842

Data are presented as n (%) or mean ± SD.

PBx, prostate biopsy; PSA, prostate cancer-specific antigen; PSAV, PSA velocity.